CL2013000310A1 - Compuestos derivados de tetrahidrofuranilo disustituidos y sus sales, como antagonistas del receptor b1 de bradiquinina; medicamento que contiene a dichos compuestos; su procedimiento de preparacion, util para el tratamiento agudo o profilactico de dolores agudos, osteoartritis, asma, alergias, entre otras enfermedades. - Google Patents

Compuestos derivados de tetrahidrofuranilo disustituidos y sus sales, como antagonistas del receptor b1 de bradiquinina; medicamento que contiene a dichos compuestos; su procedimiento de preparacion, util para el tratamiento agudo o profilactico de dolores agudos, osteoartritis, asma, alergias, entre otras enfermedades.

Info

Publication number
CL2013000310A1
CL2013000310A1 CL2013000310A CL2013000310A CL2013000310A1 CL 2013000310 A1 CL2013000310 A1 CL 2013000310A1 CL 2013000310 A CL2013000310 A CL 2013000310A CL 2013000310 A CL2013000310 A CL 2013000310A CL 2013000310 A1 CL2013000310 A1 CL 2013000310A1
Authority
CL
Chile
Prior art keywords
compounds
acute
allergies
osteoarthritis
asthma
Prior art date
Application number
CL2013000310A
Other languages
English (en)
Inventor
Norbert Hauel
Angelo Ceci
Raimund Kuelzer
Henri Doods
Birgit Jung
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2013000310A1 publication Critical patent/CL2013000310A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

Compuestos derivados de tetrahidrofuranilo disustituidos y sus sales, como antagonistas del receptor B1 de bradiquinina; medicamento que contiene a dichos compuestos; su procedimiento de preparación, útil para el tratamiento agudo o profiláctico de dolores agudos, osteoartritis, asma, alergias, entre otras enfermedades.
CL2013000310A 2010-08-20 2013-01-30 Compuestos derivados de tetrahidrofuranilo disustituidos y sus sales, como antagonistas del receptor b1 de bradiquinina; medicamento que contiene a dichos compuestos; su procedimiento de preparacion, util para el tratamiento agudo o profilactico de dolores agudos, osteoartritis, asma, alergias, entre otras enfermedades. CL2013000310A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10173489 2010-08-20

Publications (1)

Publication Number Publication Date
CL2013000310A1 true CL2013000310A1 (es) 2013-04-01

Family

ID=44510978

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000310A CL2013000310A1 (es) 2010-08-20 2013-01-30 Compuestos derivados de tetrahidrofuranilo disustituidos y sus sales, como antagonistas del receptor b1 de bradiquinina; medicamento que contiene a dichos compuestos; su procedimiento de preparacion, util para el tratamiento agudo o profilactico de dolores agudos, osteoartritis, asma, alergias, entre otras enfermedades.

Country Status (36)

Country Link
US (1) US8937073B2 (es)
EP (1) EP2606042B1 (es)
JP (1) JP5727011B2 (es)
KR (1) KR101822371B1 (es)
CN (1) CN103068817B (es)
AP (1) AP2012006630A0 (es)
AR (1) AR082507A1 (es)
AU (1) AU2011290727B2 (es)
BR (1) BR112013003752A2 (es)
CA (1) CA2807086A1 (es)
CL (1) CL2013000310A1 (es)
CO (1) CO6680689A2 (es)
CY (1) CY1115933T1 (es)
DK (1) DK2606042T3 (es)
EA (1) EA022787B1 (es)
EC (1) ECSP13012495A (es)
ES (1) ES2525296T3 (es)
GE (1) GEP20146196B (es)
HK (1) HK1178902A1 (es)
HR (1) HRP20141172T1 (es)
IL (1) IL224039A (es)
MA (1) MA34578B1 (es)
ME (1) ME01899B (es)
MX (1) MX352548B (es)
MY (1) MY156233A (es)
NZ (1) NZ607435A (es)
PE (1) PE20130810A1 (es)
PL (1) PL2606042T3 (es)
PT (1) PT2606042E (es)
RS (1) RS53622B1 (es)
SG (1) SG187835A1 (es)
SI (1) SI2606042T1 (es)
TW (1) TWI548632B (es)
UA (1) UA108765C2 (es)
UY (1) UY33565A (es)
WO (1) WO2012022795A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007034620A1 (de) * 2007-07-25 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue B1-Antagonisten
CA2697946C (en) 2007-08-29 2016-06-28 Boehringer Ingelheim International Gmbh Bradykinin b1-antagonists
US8937073B2 (en) 2010-08-20 2015-01-20 Boehringer Ingelheim International Gmbh Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists
US10544117B2 (en) 2014-09-10 2020-01-28 Temple University—Of the Commonwealth System of Higher Education 5-hydroxytryptamine receptor 7 activity modulators and their method of use
US20180221365A1 (en) * 2015-05-12 2018-08-09 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
US11401303B2 (en) * 2020-06-15 2022-08-02 Taian City Qihang Biotechnology Co. Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259079B (en) * 2002-02-08 2006-08-01 Merck & Co Inc N-biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives
ES2256727T3 (es) * 2002-02-08 2006-07-16 MERCK & CO., INC. Derivados de n-bifenilmetil aminocicloalcanocarboxamida.
CA2495914A1 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. N-biarylmethyl aminocycloalkanecarboxamide derivatives
CN1832922A (zh) * 2003-08-07 2006-09-13 默克公司 磺酰基取代的n－(联芳基甲基)氨基环丙烷甲酰胺类
JP2007501790A (ja) * 2003-08-07 2007-02-01 メルク　エンド　カムパニー　インコーポレーテッド スルホニル置換ｎ−（ビアリールメチル）アミノシクロプロパンカルボキサミド
CA2557858A1 (en) * 2004-03-02 2005-09-15 Merck & Co., Inc. Amino cyclopropane carboxamide derivatives as bradykinin antagonists
US20060173023A1 (en) 2005-02-01 2006-08-03 Wood Michael R 2-(Bicyclo)alkylamino-derivatives as mediators of chronic pain and inflammation
WO2008033564A1 (en) * 2006-09-15 2008-03-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
HUP0600809A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
DE102007034620A1 (de) 2007-07-25 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue B1-Antagonisten
EP2025675A1 (de) 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamide mit analgetischer Wirkung
CA2697946C (en) 2007-08-29 2016-06-28 Boehringer Ingelheim International Gmbh Bradykinin b1-antagonists
AR068509A1 (es) * 2007-09-19 2009-11-18 Jerini Ag Antagosnistas del receptor de bradiquinina b1
WO2010057899A1 (de) 2008-11-20 2010-05-27 Boehringer Ingelheim International Gmbh Cykloalkylaminocarbonylderivate als bradykinin-b1-rezeptor antagonisten
NZ594674A (en) 2009-02-26 2013-12-20 Boehringer Ingelheim Int Compounds as bradykinin b1 antagonists
EP2539323B3 (de) * 2010-02-23 2017-10-04 Boehringer Ingelheim International GmbH Verbindungen als Bradykinin-B1-Antagonisten
WO2010097374A1 (de) 2009-02-26 2010-09-02 Boehringer Ingelheim International Gmbh Verbindungen als bradykinin-b1-antagonisten
JP5934212B2 (ja) 2010-08-20 2016-06-15 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 複数のプロスタグランジン受容体に作用し、一般的な抗炎症反応を生じる化合物
US8901127B2 (en) 2010-08-20 2014-12-02 Boehringer Ingelheim International Gmbh Pyridazin derivatives as antagonists of the bradykinin B1 receptor
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8937073B2 (en) 2010-08-20 2015-01-20 Boehringer Ingelheim International Gmbh Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1

Also Published As

Publication number Publication date
AU2011290727A1 (en) 2013-03-14
US8937073B2 (en) 2015-01-20
EA201201662A1 (ru) 2013-07-30
EP2606042B1 (de) 2014-09-03
HRP20141172T1 (hr) 2015-02-13
ECSP13012495A (es) 2013-04-30
GEP20146196B (en) 2014-11-10
TW201305145A (zh) 2013-02-01
MX352548B (es) 2017-11-29
TWI548632B (zh) 2016-09-11
JP2013534238A (ja) 2013-09-02
AU2011290727B2 (en) 2015-07-16
EA022787B1 (ru) 2016-03-31
AR082507A1 (es) 2012-12-12
PE20130810A1 (es) 2013-07-25
SI2606042T1 (sl) 2014-12-31
PL2606042T3 (pl) 2015-03-31
WO2012022795A1 (de) 2012-02-23
MA34578B1 (fr) 2013-10-02
CN103068817B (zh) 2014-10-29
DK2606042T3 (da) 2014-12-08
SG187835A1 (en) 2013-03-28
HK1178902A1 (en) 2013-09-19
CY1115933T1 (el) 2017-01-25
CO6680689A2 (es) 2013-05-31
US20120208823A1 (en) 2012-08-16
MY156233A (en) 2016-01-29
UY33565A (es) 2012-03-30
JP5727011B2 (ja) 2015-06-03
ES2525296T3 (es) 2014-12-19
KR20130114082A (ko) 2013-10-16
MX2013001965A (es) 2013-05-09
BR112013003752A2 (pt) 2016-05-31
UA108765C2 (xx) 2015-06-10
NZ607435A (en) 2015-07-31
ME01899B (me) 2014-12-20
RS53622B1 (en) 2015-04-30
AP2012006630A0 (en) 2012-12-31
EP2606042A1 (de) 2013-06-26
PT2606042E (pt) 2014-10-15
KR101822371B1 (ko) 2018-01-31
CA2807086A1 (en) 2012-02-23
IL224039A (en) 2016-03-31
CN103068817A (zh) 2013-04-24

Similar Documents

Publication Publication Date Title
CL2013000310A1 (es) Compuestos derivados de tetrahidrofuranilo disustituidos y sus sales, como antagonistas del receptor b1 de bradiquinina; medicamento que contiene a dichos compuestos; su procedimiento de preparacion, util para el tratamiento agudo o profilactico de dolores agudos, osteoartritis, asma, alergias, entre otras enfermedades.
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CL2014003388A1 (es) Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades.
CR20150370A (es) Compuestos antivirales
CR20150217A (es) Inhibidores de histona demetilasas
CR20150326A (es) Inhibidores de autotaxina
EA201300388A1 (ru) Соединения замещенного бензамида
DOP2017000013A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
UY33735A (es) Compuestos antivirales
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
MA34091B1 (fr) Anticorps anti-cd40
ECSP13012719A (es) Compuesto bicíclico
BR112012001372A2 (pt) comprimido, e, métodos para preparar um comprimido e para a profilaxia ou tratamento de hiperfosfatemia.
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
CL2014002661A1 (es) Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer.
GT201400090A (es) 2-tiopirimidinonas
CL2012003681A1 (es) Compuestos derivados de piperidina; composicion farmaceutica; y su uso como inhibidores de acetil-coa carboxilasa para el tratamiento de trastornos metabolicos, tales como obesidad y diabetes.
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
BR112012023836A2 (pt) composto tricíclicos e inibidores de pbk contendo os mesmos
BR112017006552A2 (pt) composições e métodos para inibir a atividade biológica de biomoléculas solúveis
EA201170672A1 (ru) Соединения, пригодные для лечения целлюлита
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.